Akero Therapeutics Inc

NASDAQ:AKRO 4:00:00 PM EDT

18.93

-1.33 (-6.56%)

5:31:37 PM EDT: $18.90 -0.03 (-0.16%)

Akero Therapeutics Inc Stock, NASDAQ:AKRO

601 Gateway Boulevard, Suite 350, South San Francisco, California 94080-7006

United States of America

Phone: +1.650.487.6488

Number of Employees: 56

http://www.akerotx.com

Description

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.